LKFT Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.…
Industry Peers
BiotechnologyKey Statistics
About Lakefront Biotherapeutics (AMS: LKFT)
›
Lakefront Biotherapeutics (AMS: LKFT) is listed on Euronext Amsterdam, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 196 employees.
The shares were at 30.88 EUR on 19 November 2026, up 16.6% over 52 weeks. Its 52-week range is 22.32 EUR to 32.08 EUR: the price is 3.7% below the high and 38.4% above the low.
At a market capitalisation of 2.03B EUR, it trades at 2.6 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 92% for LKFT.
Lakefront Biotherapeutics reports return on equity of 9.9%, an operating margin of 57.5% and revenue down 81.5% year over year.
It holds more cash than debt, a net cash position of 2.23B EUR. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Hold; their mean price target of 32.61 EUR is 5.6% above the current price. The next earnings report is expected on 24 February 2027.